SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-410997"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-410997" > Blood Chromogranin ...

  • Matar, SomerWren Labs, Branford, CT USA. (författare)

Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • 2019-04-16
  • S. Karger AG,2020
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-410997
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-410997URI
  • https://doi.org/10.1159/000500202DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Background: Identification of circulating tumor markers for clinical management in bronchopulmonary (BP) neuroendocrine tumors/neoplasms (NET/NEN) is of considerable clinical interest. Chromogranin A (CgA), a "universal" NET biomarker, is considered controversial as a circulating biomarker of BPNEN.Aim: Assess utility of CgA in the diagnosis and management of BPNEN in a multicentric study.Material and Methods: CgA diagnostic metrics were assessed in lung NET/NENs (n = 200) and controls (n = 140), randomly assigned to a Training and Test set (100 BPC and 70 controls in each). Assay specificity was evaluated in neoplastic lung disease (n = 137) and nonneoplastic lung disease (n = 77). CgA efficacy in predicting clinical status was evaluated in the combined set of 200 NET/NENs. CgA levels in bronchopulmonary neuroendocrine tumor (BPNET) subtypes (atypical [AC] vs. typical [TC]) and grade was examined. The clinical utility of an alteration of CgA levels (+/- 25%) was evaluated in a subset of 49 BPNET over 12 months. CgA measurement was by NEOLISA(TM) kit (EuroDiagnostica).Results: Sensitivity and specificity in the training set were 41/98%, respectively. Test set data were 42/87%. Training set area under receiver operator characteristic analysis differentiated BPC from control area under the curve (AUC) 0.61 +/- 0.05 p = 0.015. Test set the data were AUC 0.58 +/- 0.05, p = 0.076. In the combined set (n = 200), 67% BPNET/NEN (n = 134) had normal CgA levels. CgA levels did not distinguish histological subtypes (TC vs. AC, AUC 0.56 +/- 0.04, p = 0.21), grade (p = 0.45-0.72), or progressive from stable disease (AUC 0.53 +/- 0.05 p = 0.47). There was no correlation of CgA with Ki-67 index (Pearson r = 0.143, p = 0.14). For nonneoplastic diseases (chronic obstructive pulmonary disorder and idiopathic pulmonary fibrosis), CgA was elevated in 26-37%. For neoplastic disease (NSCLC, squamous cell carcinoma), CgA was elevated in 11-16%. The neuroendocrine SCLC also exhibited elevated CgA (50%). Elevated CgA was not useful for differentiating BPNET/NEN from these other pathologies. Monitoring BPNET/NEN over a 12-month period identified neither CgA levels per se nor changes in CgA were reflective of somatostatin analog treatment outcome/efficacy or the natural history of the disease (progression).Conclusions: Blood CgA levels are not clinically useful as a biomarker for lung BPNET/NEN. The low specificity and elevations in both nonneoplastic as well as other common neoplastic lung diseases identified limited clinical utility for this biomarker.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Malczewska, AnnaYale Univ, Sch Med, Sect Digest Dis, New Haven, CT USA.;Med Univ Silesia, Dept Endocrinol & Neuroendocrine Tumors, Katowice, Poland. (författare)
  • Öberg, Kjell,1946-Uppsala universitet,Endokrin tumörbiologi(Swepub:uu)kjellob (författare)
  • Bodei, LisaMem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA. (författare)
  • Aslanian, HarryYale Univ, Sch Med, Sect Digest Dis, New Haven, CT USA. (författare)
  • Lewczuk-Myslicka, AnnaMed Univ Gdansk, Dept Endocrinol & Internal Med, Gdansk, Poland. (författare)
  • Filosso, Pier LuigiUniv Turin, Dept Thorac Surg, Turin, Italy. (författare)
  • Suarez, Alejandro L.Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT USA. (författare)
  • Kolasinska-Cwikla, AgnieszkaMaria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland. (författare)
  • Roffinella, MatteoUniv Turin, Dept Thorac Surg, Turin, Italy. (författare)
  • Kos-Kudla, BeataMed Univ Silesia, Dept Endocrinol & Neuroendocrine Tumors, Katowice, Poland. (författare)
  • Cwikla, Jaroslaw B.Univ Warmia & Mazury, Dept Radiol, Olsztyn, Poland. (författare)
  • Drozdov, Ignat A.Wren Labs, Branford, CT USA. (författare)
  • Kidd, MarkWren Labs, Branford, CT USA. (författare)
  • Modlin, Irvin M.Yale Univ, Sch Med, Gastroenterol & Endoscop Surg, New Haven, CT USA. (författare)
  • Wren Labs, Branford, CT USA.Yale Univ, Sch Med, Sect Digest Dis, New Haven, CT USA.;Med Univ Silesia, Dept Endocrinol & Neuroendocrine Tumors, Katowice, Poland. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Neuroendocrinology: S. Karger AG110:3-4, s. 185-1970028-38351423-0194

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy